NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Structured Abstract
Background:
Lung cancer is the leading cause of cancer-related death in the United States. However, persons with early lung cancer have lower lung cancer–related mortality than those with extensive disease, suggesting early detection and treatment of lung cancer might be beneficial. Low-dose computed tomography (LDCT) and chest x-ray (CXR) have been studied for early screening, with several new studies reporting results since the last review.
Purpose:
To update the 2004 review of screening for lung cancer for the U.S. Preventive Services Task Force.
Data Sources:
MEDLINE (2000 to 2012), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through fourth quarter 2012), Scopus, and reference lists.
Study Selection:
English-language randomized, controlled trials or cohort studies that evaluated screening or treatment interventions for lung cancer and reported health outcomes.
Data Extraction:
Details about participants, study design, analysis, followup, and results were abstracted; study quality was rated using established criteria, where applicable.
Data Synthesis (Results):
Four trials reported the effectiveness of screening with LDCT for lung cancer in patients with personal smoking exposure: one large good-quality trial reported screening was associated with reduced lung cancer and all-cause mortality reductions of 20 percent (95% CI, 6.8 to 27.6) and 6.7 percent (95% CI, 1.2 to 13.6), respectively. Three small European trials (two fair- and one poor-quality) showed no benefit of screening. When the three good- or fair-quality trials were combined in random effects meta-analysis, the relative risk of lung cancer mortality was 0.81 (95% CI, 0.72 to 0.91). One trial evaluated CXR screening in over 150,000 participants from the general population and reported no benefit of screening in this group or in a subset with personal tobacco smoke exposure. The reported sensitivity of LDCT for detecting lung cancer ranged from 80 to 100 percent and specificity from 28 to 100 percent in six studies; each study varied in its reporting method. The harms associated with LDCT screening included radiation exposure ranging from 0.61 to 1.5 mSv per scan, some degree of overdiagnosis of lung cancer that varied by study, and a high rate of false-positive examinations, which were typically resolved with further imaging. Most patients with positive results who underwent an invasive procedure were diagnosed with lung cancer. Smoking cessation was not significantly impacted by screening, although individuals with positive or indeterminate screens showed a trend toward reduced smoking or sustained abstinence. Patients with positive or indeterminate scans had some evidence of short-term increases in anxiety and distress but not long-term in the five studies evaluating this; patients with negative scans had a reduction in distress. Finally, no trials comparing treatment of stage I non-small cell lung cancer (NSCLC) with no treatment have been conducted. However, survival associated with surgical resection was evaluated in 11 studies of mostly symptomatic and unselected patients that have shown 5-year survival rates in the 71 to 90 percent range for stage IA NSCLC and 42 to 75 percent for stage IB NSCLC and that surgical resection is the U.S. standard of care. Harms of treatment of stage I NSCLC were poorly reported and ranged among the studies that reported them.
Limitations:
Three trials were underpowered and of too short of duration to reach conclusions on effectiveness of screening. Overdiagnosis is an important harm of screening but its magnitude is uncertain. No studies of LDCT have reported results in women or minority populations.
Conclusions:
Good evidence shows LDCT can significantly reduce mortality from lung cancer. However, there are significant harms associated with screening that must be balanced with the benefits. More efforts to reduce false-positive examinations are of paramount importance and smoking cessation remains the most important approach to reducing lung cancer mortality.
Contents
- 1. INTRODUCTION
- 2. METHODS
- 3. RESULTS
- Description of Randomized, Controlled Trials
- Key Question 1 How Effective Is Screening for Lung Cancer in Reducing Mortality and Morbidity?
- Key Question 2 What Are the Test Characteristics of Screening Tests for Lung Cancer?
- Key Question 3 What Are the Harms Associated With Lung Cancer Screening and Are There Ways to Modify Harms?
- Key Question 4 How Effective Is the Treatment of Surgical Resection of Early (Stage IA) Non-Small Cell Lung Cancer?
- Key Question 5 What Are the Harms Associated With Surgical Resection of Early (Stage IA) Non-Small Cell Lung Cancer?
- 4. DISCUSSION
- References
- Appendix A Detailed Methods
- Appendix B Evidence Tables and Quality Tables
Acknowledgements: The authors acknowledge Andrew Hamilton, MLS, MS, for assistance with literature searches and Amanda Brunton, BS, for assistance with preparing this report. We also thank AHRQ Officers Jennifer Croswell, MD, MPH, Mary Barton, MD, MPP, Tracy Wolff, MD, MPH, and Tess Miller, DrPH, and USPSTF leads Sue Curry, PhD, Mike LeFevre, MD, MSPH, Virginia Moyer, MD, MPH, and Doug Owens, MD, MS, for their contributions to this report.
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services1, Contract No. HHSA-290-2007-10057-I-EPC3, Task Order No. 13. Prepared by: Pacific Northwest Evidence-based Practice Center2,
Suggested citation:
Humphrey L, Deffebach M, Pappas M, Baumann C, Artis K, Priest Mitchell J, Zakher B, Fu R, Slatore C. Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 105. AHRQ Publication No. 13-05188-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). The investigators involved have declared no conflicts of interest with objectively conducting this research. The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.
The report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
- 1
540 Gaither Road, Rockville, MD 20850; www
.ahrq.gov - 2
Oregon Health & Science University, Mail Code: BICC, 3181 SW Sam Jackson Park Road, Portland, OR 97239; www
.ohsu.edu/epc
- NLM CatalogRelated NLM Catalog Entries
- Review Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force[ 2021]Review Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task ForceJonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, Enyioha C, Malo TL, Brenner AT, Armstrong C, et al. 2021 Mar
- Review Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the U.S. Preventive Services Task ForceGuirguis-Blake JM, Senger CA, Webber EM, Mularski R, Whitlock EP. 2016 Apr
- Review Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task ForceLin JS, Piper MA, Perdue LA, Rutter C, Webber EM, O’Connor E, Smith N, Whitlock EP. 2016 Jun
- Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task ForceWernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. 2016 Jul
- Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. 2016 Aug
- Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Servi...Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation
Your browsing activity is empty.
Activity recording is turned off.
See more...